Abhishek Puthenveetil

Ramat Gan, TA 52900, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Leveraging the active conformation of LFA-1 as a potential target for hematological malignancies.

Leveraging the active conformation of LFA-1 as a potential target for hematological malignancies.

Journal: Molecular therapy. Methods & clinical development

Published: June 10, 2025

Isolation and characterization of primary NK cells and the enrichment of the KIR2DL1+ population.

Isolation and characterization of primary NK cells and the enrichment of the KIR2DL1+ population.

Journal: Methods in cell biology

Published: February 07, 2025

Dysfunctional natural killer cells can be reprogrammed to regain anti-tumor activity.

Dysfunctional natural killer cells can be reprogrammed to regain anti-tumor activity.

Journal: The EMBO journal

Published: October 01, 2023

Actin Retrograde Flow Regulated by the Wiskott-Aldrich Syndrome Protein Drives the Natural Killer Cell Response.

Actin Retrograde Flow Regulated by the Wiskott-Aldrich Syndrome Protein Drives the Natural Killer Cell Response.

Journal: Cancers

Published: July 21, 2022

Inhibition of SHP-1 activity by PKC-θ regulates NK cell activation threshold and cytotoxicity.

Inhibition of SHP-1 activity by PKC-θ regulates NK cell activation threshold and cytotoxicity.

Journal: eLife

Published: August 23, 2021

Modulation of intrinsic inhibitory checkpoints using nano-carriers to unleash NK cell activity.

Modulation of intrinsic inhibitory checkpoints using nano-carriers to unleash NK cell activity.

Journal: EMBO molecular medicine

Published: February 03, 2021

Metabolic reprograming of tumor-associated macrophages.

Metabolic reprograming of tumor-associated macrophages.

Journal: Annals of translational medicine

Published: September 21, 2020

Targeting the actin nucleation promoting factor WASp provides a therapeutic approach for hematopoietic malignancies.

Targeting the actin nucleation promoting factor WASp provides a therapeutic approach for hematopoietic malignancies.

Journal: Nature communications

Published: March 16, 2020

Showing 1-8 of 8

Last Updated: 09/26/2026